EP3411482A4 - Antibodies and elisas for alpha klotho - Google Patents

Antibodies and elisas for alpha klotho Download PDF

Info

Publication number
EP3411482A4
EP3411482A4 EP17746682.8A EP17746682A EP3411482A4 EP 3411482 A4 EP3411482 A4 EP 3411482A4 EP 17746682 A EP17746682 A EP 17746682A EP 3411482 A4 EP3411482 A4 EP 3411482A4
Authority
EP
European Patent Office
Prior art keywords
elisas
antibodies
alpha klotho
klotho
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17746682.8A
Other languages
German (de)
French (fr)
Other versions
EP3411482A1 (en
Inventor
Sachdev S. Sidhu
Sarah L. BARKER
Orson W. MOE
Makoto Kuro-O
Johanne PASTOR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
University of Texas System
Original Assignee
University of Toronto
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto, University of Texas System filed Critical University of Toronto
Publication of EP3411482A1 publication Critical patent/EP3411482A1/en
Publication of EP3411482A4 publication Critical patent/EP3411482A4/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541—Double or second antibody, i.e. precipitating antibody
EP17746682.8A 2016-02-03 2017-02-03 Antibodies and elisas for alpha klotho Pending EP3411482A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290776P 2016-02-03 2016-02-03
PCT/CA2017/050127 WO2017132772A1 (en) 2016-02-03 2017-02-03 Antibodies and elisas for alpha klotho

Publications (2)

Publication Number Publication Date
EP3411482A1 EP3411482A1 (en) 2018-12-12
EP3411482A4 true EP3411482A4 (en) 2019-12-11

Family

ID=59499231

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17746682.8A Pending EP3411482A4 (en) 2016-02-03 2017-02-03 Antibodies and elisas for alpha klotho

Country Status (5)

Country Link
US (2) US10663474B2 (en)
EP (1) EP3411482A4 (en)
JP (1) JP6682641B2 (en)
CA (1) CA3012873A1 (en)
WO (1) WO2017132772A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6612324B2 (en) 2014-07-31 2019-11-27 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント Antibody with high affinity for αKlotho
EP3411482A4 (en) 2016-02-03 2019-12-11 The Governing Council of the University of Toronto Antibodies and elisas for alpha klotho
AU2018313853A1 (en) 2017-08-08 2020-01-02 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013080055A2 (en) * 2011-09-27 2013-06-06 The Governing Council Of The University Of Toronto Molecular display method
US20150337037A1 (en) 2012-06-05 2015-11-26 Msm Protein Technologies Human monoclonal antibodies against human chemokine receptor ccr6
JP6612324B2 (en) 2014-07-31 2019-11-27 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント Antibody with high affinity for αKlotho
WO2016019456A1 (en) 2014-08-07 2016-02-11 TrustPoint Innovation Technologies, Ltd. Id tag authentication system and method
CA2979895A1 (en) 2015-03-18 2016-09-22 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
EP3411482A4 (en) 2016-02-03 2019-12-11 The Governing Council of the University of Toronto Antibodies and elisas for alpha klotho

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAZAKI Y ET AL: "Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 398, no. 3, 30 July 2010 (2010-07-30), pages 513 - 518, XP027185031, ISSN: 0006-291X, [retrieved on 20100701], DOI: 10.1016/J.BBRC.2010.06.110 *

Also Published As

Publication number Publication date
US11143661B2 (en) 2021-10-12
WO2017132772A1 (en) 2017-08-10
US20190041402A1 (en) 2019-02-07
US20200300867A1 (en) 2020-09-24
JP6682641B2 (en) 2020-04-15
US10663474B2 (en) 2020-05-26
JP2019513004A (en) 2019-05-23
EP3411482A1 (en) 2018-12-12
CA3012873A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
EP3723803A4 (en) Anti-trem2 antibodies and related methods
EP3572427A4 (en) Bcma-targeting antibody and use thereof
EP3504243A4 (en) Anti-tim-3 antibodies and use thereof
EP3383916A4 (en) Anti-cd73 antibodies and uses thereof
EP3625263A4 (en) Anti-galectin-9 antibodies and uses thereof
EP3483182A4 (en) Antibody for anti-claudin 18a2 and use thereof
EP3386536A4 (en) Composition of antibody construct-agonist conjugates and methods of use thereof
EP3389702A4 (en) Anti-lag-3 antibodies and uses thereof
EP3333192A4 (en) Antibody against glypican-3 and application thereof
EP3596119A4 (en) Anti-phf-tau antibodies and uses thereof
EP3426288A4 (en) Anti-pacap antibodies and uses thereof
EP3397276A4 (en) Antibodies and conjugates thereof
EP3155018A4 (en) Constant region antibody fusion proteins and compositions thereof
EP3316909A4 (en) Anti-ntb-a antibodies and related compositions and methods
EP3283516A4 (en) Anti-pacap antibodies and uses thereof
EP3341021A4 (en) Anti-alk antibodies and methods for use thereof
EP3442567A4 (en) Anti-psma antibodies and use thereof
EP3439741A4 (en) Alk7 antagonists and uses thereof
EP3733702A4 (en) Anti-lag-3 antibody and uses thereof
EP3645563A4 (en) Anti-fam19a5 antibodies and uses thereof
EP3290441A4 (en) RGMa BINDING PROTEIN AND USE THEREOF
EP3567054A4 (en) Anti-alpha-syn antibody and use thereof
EP3672987A4 (en) Anti-apelin antibodies and uses thereof
EP3600421A4 (en) Anti-c5a antibodies and uses thereof
AU2017271189A1 (en) Cytosol-penetrating antibody and use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180802

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Owner name: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191108

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20191104BHEP

Ipc: G01N 33/573 20060101ALI20191104BHEP

Ipc: C07K 16/18 20060101ALI20191104BHEP

Ipc: C12N 15/13 20060101AFI20191104BHEP

Ipc: A61K 39/395 20060101ALI20191104BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220706

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN